Toggle navigation
Search
Tree View
MeSH on Demand
MeSH 2024
About
Suggestions
Contact Us
Certolizumab Pegol
MeSH Descriptor Data 2025
Details
Qualifiers
MeSH Tree Structures
Concepts
MeSH Heading
Certolizumab Pegol
Tree Number(s)
D05.750.741.125
D12.644.541.500.650.250
D12.776.124.486.485.114.224.060.500
D12.776.124.486.485.680.650.250
D12.776.124.790.651.114.224.060.500
D12.776.124.790.651.680.650.250
D12.776.377.715.548.114.224.200.500
D12.776.377.715.548.680.650.250
Unique ID
D000068582
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000068582
Scope Note
A polyethylene-glycolated Fab' fragment of
TUMOR NECROSIS FACTOR
antibody that binds specifically to
TNF-ALPHA
and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced
TNF-ALPHA
and
IL-1 BETA
and is used to treat
RHEUMATOID ARTHRITIS
and
PSORIATIC ARTHRITIS
.
Entry Term(s)
CDP 870
CDP870
Cimzia
Pharm Action
Immunosuppressive Agents
Antirheumatic Agents
Tumor Necrosis Factor Inhibitors
Related Numbers
428863-50-7
See Also
Tumor Necrosis Factor-alpha
Public MeSH Note
2016; CERTILIZUMAB PEGOL was indexed under IMMUNOGLOBULIN FAB FRAGMENTS 2003-2015, POLYETHYLENE GLYCOLS 2003-2015, and under ANTIBODIES, MONOCLONAL, HUMANIZED 2003-2015
History Note
2016 (2003)
Date Established
2016/01/01
Date of Entry
2015/07/10
Revision Date
2021/07/01
Allowable Qualifiers
administration & dosage (AD)
adverse effects (AE)
analysis (AN)
biosynthesis (BI)
blood (BL)
cerebrospinal fluid (CF)
chemistry (CH)
classification (CL)
drug effects (DE)
economics (EC)
genetics (GE)
history (HI)
immunology (IM)
isolation & purification (IP)
metabolism (ME)
pharmacokinetics (PK)
pharmacology (PD)
physiology (PH)
poisoning (PO)
radiation effects (RE)
therapeutic use (TU)
toxicity (TO)
ultrastructure (UL)
urine (UR)
Macromolecular Substances [D05]
Polymers [D05.750]
Polyethylene Glycols [D05.750.741]
Certolizumab Pegol [D05.750.741.125]
Cetomacrogol [D05.750.741.250]
Hydrogel, Polyethylene Glycol Dimethacrylate [D05.750.741.485]
Nonoxynol [D05.750.741.575]
Octoxynol [D05.750.741.610]
Polidocanol [D05.750.741.630]
Poloxalene [D05.750.741.650]
Poloxamer [D05.750.741.667]
Polyhydroxyethyl Methacrylate [D05.750.741.685]
Polysorbates [D05.750.741.700]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Peptide Fragments [D12.644.541]
Immunoglobulin Fragments [D12.644.541.500]
Immunoglobulin Fab Fragments [D12.644.541.500.650]
Abciximab [D12.644.541.500.650.125]
Certolizumab Pegol [D12.644.541.500.650.250]
Immunoglobulin Variable Region [D12.644.541.500.650.500]
Tuftsin [D12.644.541.500.650.750]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Antibodies, Monoclonal [D12.776.124.486.485.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
Abciximab [D12.776.124.486.485.114.224.060.125]
Adalimumab [D12.776.124.486.485.114.224.060.250]
Alemtuzumab [D12.776.124.486.485.114.224.060.313]
Basiliximab [D12.776.124.486.485.114.224.060.344]
Bevacizumab [D12.776.124.486.485.114.224.060.375]
Brentuximab Vedotin [D12.776.124.486.485.114.224.060.438]
Certolizumab Pegol [D12.776.124.486.485.114.224.060.500]
Cetuximab [D12.776.124.486.485.114.224.060.750]
Daclizumab [D12.776.124.486.485.114.224.060.766]
Denosumab [D12.776.124.486.485.114.224.060.782]
Gemtuzumab [D12.776.124.486.485.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.486.485.114.224.060.794]
Ipilimumab [D12.776.124.486.485.114.224.060.798]
Natalizumab [D12.776.124.486.485.114.224.060.813]
Nivolumab [D12.776.124.486.485.114.224.060.829]
Omalizumab [D12.776.124.486.485.114.224.060.844]
Palivizumab [D12.776.124.486.485.114.224.060.860]
Panitumumab [D12.776.124.486.485.114.224.060.864]
Ramucirumab [D12.776.124.486.485.114.224.060.866]
Ranibizumab [D12.776.124.486.485.114.224.060.868]
Trastuzumab [D12.776.124.486.485.114.224.060.875]
Ustekinumab [D12.776.124.486.485.114.224.060.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Immunoglobulin Fragments [D12.776.124.486.485.680]
Immunoglobulin Fab Fragments [D12.776.124.486.485.680.650]
Abciximab [D12.776.124.486.485.680.650.125]
Certolizumab Pegol [D12.776.124.486.485.680.650.250]
Immunoglobulin Variable Region [D12.776.124.486.485.680.650.500]
Tuftsin [D12.776.124.486.485.680.650.750]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Antibodies, Monoclonal [D12.776.124.790.651.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
Abciximab [D12.776.124.790.651.114.224.060.125]
Adalimumab [D12.776.124.790.651.114.224.060.250]
Alemtuzumab [D12.776.124.790.651.114.224.060.375]
Basiliximab [D12.776.124.790.651.114.224.060.407]
Bevacizumab [D12.776.124.790.651.114.224.060.438]
Brentuximab Vedotin [D12.776.124.790.651.114.224.060.469]
Certolizumab Pegol [D12.776.124.790.651.114.224.060.500]
Cetuximab [D12.776.124.790.651.114.224.060.750]
Daclizumab [D12.776.124.790.651.114.224.060.766]
Denosumab [D12.776.124.790.651.114.224.060.782]
Gemtuzumab [D12.776.124.790.651.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.790.651.114.224.060.794]
Ipilimumab [D12.776.124.790.651.114.224.060.798]
Natalizumab [D12.776.124.790.651.114.224.060.813]
Nivolumab [D12.776.124.790.651.114.224.060.829]
Omalizumab [D12.776.124.790.651.114.224.060.844]
Palivizumab [D12.776.124.790.651.114.224.060.860]
Panitumumab [D12.776.124.790.651.114.224.060.864]
Ramucirumab [D12.776.124.790.651.114.224.060.866]
Ranibizumab [D12.776.124.790.651.114.224.060.868]
Trastuzumab [D12.776.124.790.651.114.224.060.875]
Ustekinumab [D12.776.124.790.651.114.224.060.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Immunoglobulin Fragments [D12.776.124.790.651.680]
Immunoglobulin Fab Fragments [D12.776.124.790.651.680.650]
Abciximab [D12.776.124.790.651.680.650.125]
Certolizumab Pegol [D12.776.124.790.651.680.650.250]
Immunoglobulin Variable Region [D12.776.124.790.651.680.650.500]
Tuftsin [D12.776.124.790.651.680.650.750]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Antibodies, Monoclonal [D12.776.377.715.548.114.224]
Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Abciximab [D12.776.377.715.548.114.224.200.125]
Adalimumab [D12.776.377.715.548.114.224.200.250]
Alemtuzumab [D12.776.377.715.548.114.224.200.375]
Basiliximab [D12.776.377.715.548.114.224.200.407]
Bevacizumab [D12.776.377.715.548.114.224.200.438]
Brentuximab Vedotin [D12.776.377.715.548.114.224.200.469]
Certolizumab Pegol [D12.776.377.715.548.114.224.200.500]
Cetuximab [D12.776.377.715.548.114.224.200.750]
Daclizumab [D12.776.377.715.548.114.224.200.766]
Denosumab [D12.776.377.715.548.114.224.200.782]
Gemtuzumab [D12.776.377.715.548.114.224.200.790]
Inotuzumab Ozogamicin [D12.776.377.715.548.114.224.200.794]
Ipilimumab [D12.776.377.715.548.114.224.200.798]
Natalizumab [D12.776.377.715.548.114.224.200.813]
Nivolumab [D12.776.377.715.548.114.224.200.829]
Omalizumab [D12.776.377.715.548.114.224.200.844]
Palivizumab [D12.776.377.715.548.114.224.200.860]
Panitumumab [D12.776.377.715.548.114.224.200.864]
Ramucirumab [D12.776.377.715.548.114.224.200.866]
Ranibizumab [D12.776.377.715.548.114.224.200.868]
Trastuzumab [D12.776.377.715.548.114.224.200.875]
Ustekinumab [D12.776.377.715.548.114.224.200.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Immunoglobulin Fragments [D12.776.377.715.548.680]
Immunoglobulin Fab Fragments [D12.776.377.715.548.680.650]
Abciximab [D12.776.377.715.548.680.650.125]
Certolizumab Pegol [D12.776.377.715.548.680.650.250]
Immunoglobulin Variable Region [D12.776.377.715.548.680.650.500]
Tuftsin [D12.776.377.715.548.680.650.750]
Expand All
Collapse All
Certolizumab Pegol
Preferred
Concept UI
M0507051
Related Numbers
428863-50-7
Scope Note
A polyethylene-glycolated Fab' fragment of
TUMOR NECROSIS FACTOR
antibody that binds specifically to
TNF-ALPHA
and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced
TNF-ALPHA
and
IL-1 BETA
and is used to treat
RHEUMATOID ARTHRITIS
and
PSORIATIC ARTHRITIS
.
Terms
Certolizumab Pegol
Preferred Term
Term UI
T000876351
Date
03/06/2015
LexicalTag
NON
ThesaurusID
CDP870
Narrower
Concept UI
M0442269
Terms
CDP870
Preferred Term
Term UI
T526395
Date
11/19/2002
LexicalTag
LAB
ThesaurusID
NLM (2002)
CDP 870
Term UI
T526396
Date
11/19/2002
LexicalTag
LAB
ThesaurusID
NLM (2002)
Cimzia
Narrower
Concept UI
M0522752
Terms
Cimzia
Preferred Term
Term UI
T794930
Date
08/05/2011
LexicalTag
TRD
ThesaurusID
NLM (2012)
page delivered in 0.157s
